Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomized, Placebo-Controlled, 3-way Crossover Study to Evaluate the Single Dose Effects of Intranasal Esketamine on Safety of On-Road Driving in Healthy Subjects

Next Previous
Search
Trial Profile

A Double-blind, Randomized, Placebo-Controlled, 3-way Crossover Study to Evaluate the Single Dose Effects of Intranasal Esketamine on Safety of On-Road Driving in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 May 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esketamine (Primary) ; Mirtazapine
  • Indications Major depressive disorder
  • Focus Pharmacodynamics
  • Acronyms DRiVESaFe
  • Sponsors Janssen Research & Development

    • Most Recent Events

    • 29 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 27 Oct 2014 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.
    • 23 Oct 2014 Planned initiation date changed from 1 Aug 2014 to 1 Sep 2014, as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top